Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in Bangladesh

Neurology

Volumn 74, Issue 7, 2010, Pages 581-587

  Islam, Z ^a,b   Jacobs, B C ^c   Van Belkum, A ^b   Mohammad, Q D ^d   Islam, M B ^d   Herbrink, P ^e   Diorditsa, S ^f   Luby, S P ^a   Talukder, K A ^a   Endtz, H P ^a,b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b Med Microbiol Infectious Disease   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d DHAKA MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^e REINIER DE GRAAF HOSPITAL   (Netherlands)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ARTIFICIAL VENTILATION; BANGLADESH; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CONTROLLED STUDY; CRANIAL NEUROPATHY; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RURAL AREA;

EID: 77149173477     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181cff735     Document Type: Article

References (72)

1. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-950.
2. Kaldor J, Speed BR. Guillain-Barré syndrome and Campy-lobacter jejuni: a serological study. BMJ 1984;288:1867-1870. (Pubitemid 14081739)
3. Mishu B, Ilyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993;118: 947-953. (Pubitemid 23164132)
4. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campy-lobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
5. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118: 597-605.
6. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-1115.
7. Koga M, Ang CW, Yuki N, et al. Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands. J Neurol Neuro-surg Psychiatry 2001;70:693-695.
8. Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S. Preceding infections and anti-ganglioside antibodies in patients with Guillain- Barré syndrome: a single centre prospective case-control study. Clin Microbiol Infect 2007; 13:334-337.
9. Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology 2007;69:1665-1671.
10. Yuki N, Yamada M, Sato S, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 1993;16:642-647.
11. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campy-lobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-187.
12. van der Meché FG, Visser LH, Jacobs BC, Endtz HP, Meulstee J, van Doorn PA. Guillain-Barré syndrome: mul-tifactorial mechanisms versus defined subgroups. J Infect Dis 1997;176:S99-S102.
13. Hadden RD, Karch H, Hartung HP, et al; Plasma Ex-change/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-765.
14. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-631.
15. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-594.
16. Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology 1999;53:2122-2127.
17. Jacobs BC, Hazenberg MP, van Doorn PA, Endtz HP, van der Meché FG. Cross-reactive antibodies against ganglio-sides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 1997;175:729-733.
18. World Health Organization. EPI Surveillance Bulletin 2008, Vol.11, No.5. Available at: http://www.whoban. org/pdf/Oct-2008-Bulletin-English%20Version.pdf
19. Vaccine Preventable Disease Surveillance Bulletin. IVD 2008; Vol.12, Week 21. Available at: http://www.searo. who.int/vaccine/linkfiles/MEAVPD/ MEAVPD2007.pdf.
20. Rasul CH, Das PL, Alam S, Ahmed S, Ahmed M. Clinical profile of acute flaccid paralysis. Med J Malaysia 2002;57: 61-65.
21. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21-S24.
22. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
23. Hadden RD, Cornblath DR, Hughes RA, et al. Electro-physiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/San-doglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998;44:780-788.
24. Endtz HP, Ang CW, van Den Braak N, et al. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barre and Miller Fisher syndromes. J Clin Microbiol 2000;38:2297-2301.
25. Talukder KA, Aslam M, Islam Z, et al. Prevalence of virulence genes and cytolethal distending toxin production in Campylobacter jejuni isolates from diarrheal patients in Bangladesh. J Clin Microbiol 2008;46:1485-1488.
26. Ang CW, Krogfelt K, Herbrink P, et al. Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barre and reactive arthritis patients. Clin Microbiol Infect 2007;13:915-922.
27. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37-44.
28. van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000;54:620-625.
29. Sedano MJ, Calleja J, Canga E, Berciano J. Guillain-Barre syndrome in Cantabria, Spain: an epidemiological and clinical study. Acta Neurol Scand 1994;89:287-292.
30. Larsen JP, Kvoie G, Nyland H. Epidemiology of the Guillain-Barre syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985;71:43-47. (Pubitemid 15156250)
31. McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.
32. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
33. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barre syndrome: a reappraisal. Ann Neurol 1999;46:701-707.
34. Shafqat S, Khealani BA, Awan F, Abedin SE. Guillain-Barre syndrome in Pakistan: similarity of demyelinating and axonal variants. Eur J Neurol 2006;13:662-665.
35. Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 2004;25:61-66.
36. Wierzba TF, Abdel-Messih IA, Gharib B, et al. Campylobacter infection as a trigger for Guillain-Barre syndrome in Egypt. PLoS One 2008;3:e3674.
37. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-950.
38. Kaldor J, Speed BR. Guillain-Barré syndrome and Campy-lobacter jejuni: a serological study. BMJ 1984;288:1867-1870. (Pubitemid 14081739)
39. Mishu B, Ilyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993;118: 947-953. (Pubitemid 23164132)
40. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campy-lobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
41. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118: 597-605.
42. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-1115.
43. Koga M, Ang CW, Yuki N, et al. Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands. J Neurol Neuro-surg Psychiatry 2001;70:693-695.
44. Sinha S, Prasad KN, Jain D, Pandey CM, Jha S, Pradhan S. Preceding infections and anti-ganglioside antibodies in patients with Guillain- Barré syndrome: a single centre prospective case-control study. Clin Microbiol Infect 2007; 13:334-337.
45. Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology 2007;69:1665-1671.
46. Yuki N, Yamada M, Sato S, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 1993;16:642-647.
47. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campy-lobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-187.
48. van der Meché FG, Visser LH, Jacobs BC, Endtz HP, Meulstee J, van Doorn PA. Guillain-Barré syndrome: mul-tifactorial mechanisms versus defined subgroups. J Infect Dis 1997;176:S99-S102.
49. Hadden RD, Karch H, Hartung HP, et al; Plasma Ex-change/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-765.
50. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-631.
51. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-594.
52. Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology 1999;53:2122-2127.
53. Jacobs BC, Hazenberg MP, van Doorn PA, Endtz HP, van der Meché FG. Cross-reactive antibodies against ganglio-sides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 1997;175:729-733.
54. World Health Organization. EPI Surveillance Bulletin 2008, Vol.11, No.5. Available at: http://www.whoban. org/pdf/Oct-2008-Bulletin-English%20Version.pdf
55. Vaccine Preventable Disease Surveillance Bulletin. IVD 2008; Vol.12, Week 21. Available at: http://www.searo. who.int/vaccine/linkfiles/MEAVPD/ MEAVPD2007.pdf.
56. Rasul CH, Das PL, Alam S, Ahmed S, Ahmed M. Clinical profile of acute flaccid paralysis. Med J Malaysia 2002;57: 61-65.
57. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21-S24.
58. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
59. Hadden RD, Cornblath DR, Hughes RA, et al. Electro-physiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/San-doglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998;44:780-788.
60. Endtz HP, Ang CW, van Den Braak N, et al. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barre and Miller Fisher syndromes. J Clin Microbiol 2000;38:2297-2301.
61. Talukder KA, Aslam M, Islam Z, et al. Prevalence of virulence genes and cytolethal distending toxin production in Campylobacter jejuni isolates from diarrheal patients in Bangladesh. J Clin Microbiol 2008;46:1485-1488.
62. Ang CW, Krogfelt K, Herbrink P, et al. Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barre and reactive arthritis patients. Clin Microbiol Infect 2007;13:915-922.
63. Kuijf ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37-44.
64. van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000;54:620-625.
65. Sedano MJ, Calleja J, Canga E, Berciano J. Guillain-Barre syndrome in Cantabria, Spain: an epidemiological and clinical study. Acta Neurol Scand 1994;89:287-292.
66. Larsen JP, Kvoie G, Nyland H. Epidemiology of the Guillain-Barre syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985;71:43-47. (Pubitemid 15156250)
67. McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.
68. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
69. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barre syndrome: a reappraisal. Ann Neurol 1999;46:701-707.
70. Shafqat S, Khealani BA, Awan F, Abedin SE. Guillain-Barre syndrome in Pakistan: similarity of demyelinating and axonal variants. Eur J Neurol 2006;13:662-665.
71. Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 2004;25:61-66.
72. Wierzba TF, Abdel-Messih IA, Gharib B, et al. Campylobacter infection as a trigger for Guillain-Barre syndrome in Egypt. PLoS One 2008;3:e3674.